Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials

佐匹克隆 唑吡坦 安慰剂 荟萃分析 随机对照试验 三唑仑 医学 置信区间 麻醉 就寝时间 催眠药 失眠症 精神科 苯二氮卓 内科学 替代医学 受体 病理
作者
Michele Fornaro,Claudio Caiazza,Flavia Rossano,Flavia Cilmi,Michele De Prisco,Eduard Vieta,Trevor Thompson,Marco Solmi,André F. Carvalho,Felice Iasevoli,Andrea de Bartolomeis
出处
期刊:European Neuropsychopharmacology [Elsevier BV]
卷期号:81: 53-63 被引量:15
标识
DOI:10.1016/j.euroneuro.2024.01.011
摘要

Sleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized Mean Difference/SMD) and driving impairment rates on the first morning (co-primary outcomes) and endpoint. Risk-of-bias, global/local inconsistencies were measured, and CINeMA was used to assess the confidence in the evidence. Of 4,805 identified records, 26 cross-over RCTs were included in the systematic review, of which 22 entered the NMA, focusing on healthy subjects only. After a single administration, most molecules paralleled the placebo, outperforming zopiclone regarding SDLP. In contrast, ramelteon 8 mg, daridorexant 100 mg, zolpidem 10 mg bedtime, zolpidem middle-of-the-night 10 mg and 20 mg, mirtazapine 15-30 mg, and triazolam 0.5 mg performed significantly worse than placebo. Lemborexant 2.5-5 mg, suvorexant 15-20 mg, and zolpidem 3.5 mg middle-of-the-night associated with lower impairment than zopiclone. Repeated administration (maximum follow-up time of ten days) caused fewer residual effects than acute ones, except for flurazepam. Heterogeneity and inconsistency were negligible. Confidence in the evidence was low/very low. Sensitivity analyses confirmed the main analyses. Most FDA-approved hypnotics overlapped placebo at in-label doses, outperforming zopiclone. Repeated administration for 15 days or less reduced residual effects, warranting further research on the matter.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Cherish完成签到,获得积分10
刚刚
斯文败类的应助被WangJ1018采纳,获得10
1秒前
1秒前
T_T完成签到 ,获得积分10
1秒前
2秒前
同心源完成签到 ,获得积分20
2秒前
daomaihu发布了新的文献求助100
2秒前
2秒前
星辰完成签到,获得积分10
3秒前
3秒前
3秒前
强强的朱呀完成签到,获得积分10
3秒前
ZJJ完成签到,获得积分10
3秒前
欣慰元蝶发布了新的文献求助10
3秒前
wangzhewwe发布了新的文献求助10
4秒前
明亮的新筠完成签到,获得积分20
5秒前
mm完成签到,获得积分10
6秒前
6秒前
Hello的应助被yy采纳,获得10
6秒前
领导范儿的应助被学术智子采纳,获得10
6秒前
Owen的应助被曲凯采纳,获得10
7秒前
Hello的应助被just采纳,获得10
7秒前
7秒前
7秒前
mmmm发布了新的文献求助10
7秒前
Away完成签到,获得积分10
8秒前
搞论文小白完成签到 ,获得积分10
8秒前
8秒前
8秒前
8秒前
简单千琴完成签到,获得积分10
9秒前
Akim的应助被江漓采纳,获得30
9秒前
WUHAO发布了新的文献求助10
9秒前
洁净路灯发布了新的文献求助10
9秒前
张鑫完成签到,获得积分10
10秒前
充电宝的应助被符聪采纳,获得10
10秒前
11秒前
nan完成签到,获得积分10
11秒前
FashionBoy的应助被sir采纳,获得10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986